Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 218

Drug Profile

MT 218

Alternative Names: MT-218; ZD2-N3-Gd(HP-DO3A)

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Theranostics
  • Class Diagnostic conjugates; Gadolinium-containing contrast agents; Peptide diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Feb 2024 Molecular Theranostics plans a phase I/II trial for Prostate cancer (Diagnosis) in USA (IV) in March 2024 (NCT06262139)
  • 08 Dec 2023 Pharmacodnamics, pharmacokinetic and adverse events data from preclinical studies in Solid tumors released by Molecular Theranostics
  • 08 Dec 2023 Pharmacokinetics and adverse events data from a phase I trial in Solid tumor released by Molecular Theranostics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top